Differences between IGIV products : Impact on clinical outcome : Use of immune globulin intravenous therapy in dermatologyGELFAND, Erwin W.International immunopharmacology. 2006, Vol 6, Num 4, pp 592-599, issn 1567-5769, 8 p.Article

Anti-allergic properties of antihistaminesGELFAND, Erwin W.Journal of allergy and clinical immunology. 2003, Vol 112, Num 4, issn 0091-6749, 64 p., SUPConference Proceedings

Asthma Clinical Trials vs. Real World Effectiveness: Comparing Apples to OrangesGELFAND, Erwin W.Journal of allergy and clinical immunology. 2003, Vol 112, Num 5, issn 0091-6749, 18 p., SUPConference Proceedings

Intravenous Immune Globulin in Autoimmune and Inflammatory DiseasesGELFAND, Erwin W.The New England journal of medicine. 2012, Vol 367, Num 21, pp 2015-2025, issn 0028-4793, 11 p.Article

The importance and features of the distal airways in children and adultsGELFAND, Erwin W; KRAFT, Monica.Journal of allergy and clinical immunology. 2009, Vol 124, Num 6, issn 0091-6749, S84-S87, SUPConference Paper

Expression of functional activating and inhibitory Fcy receptors on Human B cellsRABINOVITCH, Nathan; GELFAND, Erwin W.International archives of allergy and immunology. 2004, Vol 133, Num 3, pp 285-294, issn 1018-2438, 10 p.Article

Clinical trials: Are these your patients?STORMS, William.Journal of allergy and clinical immunology. 2003, Vol 112, Num 5, pp S107-S111, issn 0091-6749, SUPConference Paper

Role of histamine in the pathophysiology of asthma: Immunomodulatory and anti-inflammatory activities of H₁-Receptor antagonistsGELFAND, Erwin W.The American journal of medicine. 2002, Vol 113, Num 9A, pp 2S-7S, issn 0002-9343Article

Il-5-induced airway eosinophilia : the key to asthma?HAMELMANN, Eckard; GELFAND, Erwin W.Immunological reviews. 2001, Vol 179, pp 182-191, issn 0105-2896Article

CD8⁺ T lymphocytes and leukotriene B₄ : Novel interactions in the persistence and progression of asthmaGELFAND, Erwin W; DAKHAMA, Azzeddine.Journal of allergy and clinical immunology. 2006, Vol 117, Num 3, pp 577-582, issn 0091-6749, 6 p.Article

H₁-Receptors: Localization and role in airway physiology and in immune functionsTOGIAS, Alkis.Journal of allergy and clinical immunology. 2003, Vol 112, Num 4, pp S60-S68, issn 0091-6749, SUPConference Paper

Clinical trial efficacy: What does it really tell you?SPAHN, Joseph.Journal of allergy and clinical immunology. 2003, Vol 112, Num 5, pp S102-S106, issn 0091-6749, SUPConference Paper

Insights into the pathogenesis of asthma utilizing murine modelsTAUBE, Christian; DAKHAMA, Azzeddine; GELFAND, Erwin W et al.International archives of allergy and immunology. 2004, Vol 135, Num 2, pp 173-186, issn 1018-2438, 14 p.Article

Considering therapeutic options in the real worldMARTIN, Richard J.Journal of allergy and clinical immunology. 2003, Vol 112, Num 5, pp S112-S115, issn 0091-6749, SUPConference Paper

Particulate levels are associated with early asthma worsening in children with persistent diseaseRABINOVITCH, Nathan; STRAND, Matthew; GELFAND, Erwin W et al.American journal of respiratory and critical care medicine. 2006, Vol 173, Num 10, pp 1098-1105, issn 1073-449X, 8 p.Article

Histamine: A mediator of inflammationMACGLASHAN, Donald JR.Journal of allergy and clinical immunology. 2003, Vol 112, Num 4, pp S53-S59, issn 0091-6749, SUPConference Paper

Antibody-directed therapy: Past, present, and futureGELFAND, Erwin W.Journal of allergy and clinical immunology. 2001, Vol 108, Num 4, pp S111-S116, issn 0091-6749, SUPConference Paper

Urine leukotriene E₄ levels are associated with decreased pulmonary function in children with persistent airway obstructionRABINOVITCH, Nathan; LENING ZHANG; GELFAND, Erwin W et al.Journal of allergy and clinical immunology. 2006, Vol 118, Num 3, pp 635-640, issn 0091-6749, 6 p.Article

Prospects for antihistamines in the treatment of asthmaNELSON, Harold S.Journal of allergy and clinical immunology. 2003, Vol 112, Num 4, pp S96-S100, issn 0091-6749, SUPConference Paper

Intravenous immunoglobulin : Properties, mode of action and practical use in dermatologyPRINS, Christa; GELFAND, Erwin W; FRENCH, Lars E et al.Acta dermato-venereologica. 2007, Vol 87, Num 3, pp 206-218, issn 0001-5555, 13 p.Article

Efficacy and safety profile of fexofenadine HCl: A unique therapeutic option in H₁-receptor antagonist treatmentMEEVES, Suzanne G; APPAJOSYULA, Sireesh.Journal of allergy and clinical immunology. 2003, Vol 112, Num 4, pp S69-S77, issn 0091-6749, SUPConference Paper

Accumulation of high levels of the p53 and p130 growth-suppressing proteins in cell lines stably over-expressing cyclin-dependent kinase 6 (cdk6)NAGASAWA, Masayuki; GELFAND, Erwin W; LUCAS, Joseph J et al.Oncogene (Basingstoke). 2001, Vol 20, Num 23, pp 2889-2899, issn 0950-9232Article

H₁-Antihistamines: More relevant than ever in the treatment of allergic disordersSIMONS, F. Estelle R.Journal of allergy and clinical immunology. 2003, Vol 112, Num 4, pp S42-S52, issn 0091-6749, SUPConference Paper

Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsivenessGELFAND, Erwin W; CUI, Zhi-Hua; TAKEDA, Katsuyuki et al.Journal of allergy and clinical immunology. 2003, Vol 112, Num 4, pp S89-S95, issn 0091-6749, SUPConference Paper

Coding-region alterations in BTK do not universally cause X-linked agammaglobulinemiaABBOTT, Jordan K; OCHS, Hans D; GELFAND, Erwin W et al.Journal of allergy and clinical immunology. 2013, Vol 132, Num 5, pp 1246-1248, issn 0091-6749, 3 p.Article